Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Reumatismo ; 70(4): 199-211, 2018 Dec 20.
Article in English | MEDLINE | ID: mdl-30570238

ABSTRACT

Paraneoplastic syndromes (PS) are a heterogeneous group of diseases related to a neoplasm, indirectly dependent on it. Diagnosis and the treatment are often a challenge for clinicians, not least because the pathogenetic mechanisms are highly complex and not entirely known. Nonetheless, in most cases, PS precede the diagnosis of malignancies, thus their identification is particularly important in addressing physicians' diagnostic work-up with regard to early cancer diagnosis. Among paraneoplastic syndromes, those of rheumatologic interest represent a large component. In this paper, we review the main rheumatic PS.


Subject(s)
Paraneoplastic Syndromes , Rheumatic Diseases , Humans , Paraneoplastic Syndromes/diagnosis , Rheumatic Diseases/diagnosis
2.
Reumatismo ; 69(1): 30-39, 2017 May 22.
Article in English | MEDLINE | ID: mdl-28535619

ABSTRACT

Osteoporosis and fractures are common and invalidating consequences of chronic glucorticoid (GC) treatment. Reliable information regarding the epidemiology of GC induced osteoporosis (GIOP) comes exclusively from the placebo group of randomized clinical trials while observational studies are generally lacking data on the real prevalence of vertebral fractures, GC dosage and primary diagnosis. The objective of this study was to evaluate the prevalence and incidence of osteoporotic fractures and to identify their major determinants (primary disease, GC dosage, bone mineral density, risk factors, specific treatment for GIOP) in a large cohort of consecutive patients aged >21 years, on chronic treatment with GC (≥5 mg prednisone - PN - equivalent) and attending rheumatology centers located all over Italy. Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) is a national multicenter cross-sectional and longitudinal observational study. 553 patients suffering from Rheumatoid Arthritis (RA), Polymyalgia Rheumatica (PMR) and Connective Tissue Diseases (CTDs) and in chronic treatment with GCs were enrolled. Osteoporotic BMD values (T score <-2.5) were observed in 28%, 38% and 35% of patients with CTDs, PMR or RA at the lumbar spine, and in 18%, 29% and 26% at the femoral neck, respectively. Before GC treatment, prevalent clinical fractures were reported by 12%, 37% and 17% of patients with CTDs, PMR, or RA, respectively. New clinical fragility fractures during GC treatment were reported by 12%, 10% and 23% of CTDs, PMR and RA patients, respectively. Vertebral fractures were the prevailing type of fragility fracture. More than 30% of patients had recurrence of fracture. An average of 80% of patients were in supplementation with calcium and/or vitamin D during treatment with GCs. Respectively, 64%, 80%, and 72% of the CTDs, PMR and RA patients were on pharmacological treatment for GIOP, almost exclusively with bisphosphonates. The GIOTTO study might provide relevant contributions to clinical practice, in particular by highlighting and quantifying in real life the prevalence of GIOP and relative fractures, the frequency of the main risk factors, and the currently sub-optimal prevention. Moreover, these results emphasize the importance of the underlying rheumatic disease on the risk of GIOP associated fractures.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Diphosphonates/therapeutic use , Glucocorticoids/adverse effects , Osteoporotic Fractures/epidemiology , Osteoporotic Fractures/prevention & control , Rheumatic Diseases/drug therapy , Vitamin D/therapeutic use , Adult , Aged , Aged, 80 and over , Arthritis, Rheumatoid/drug therapy , Cross-Sectional Studies , Female , Glucocorticoids/administration & dosage , Humans , Incidence , Italy/epidemiology , Longitudinal Studies , Male , Middle Aged , Osteoporotic Fractures/diagnosis , Polymyalgia Rheumatica/drug therapy , Prevalence , Risk Factors , Treatment Outcome
3.
Clin Rheumatol ; 36(3): 583-590, 2017 Mar.
Article in English | MEDLINE | ID: mdl-28070764

ABSTRACT

Hypovitaminosis D is increasingly reported in autoimmune diseases. We investigated the 25-OH-vitamin D (25-OH-vitD) levels in systemic sclerosis (SSc) patients, in correlation with disease's features. We measured the 25-OH-vitD serum levels in 140 consecutive patients (F/M 126/15; mean age 61 ± 15.1 years), 91 without (group A) and 49 with (group B) 25-OH-cholecalciferol supplementation. Patients of group A invariably showed low 25-OH-vitD levels (9.8 ± 4.1 ng/ml vs. 26 ± 8.1 ng/ml of group B); in particular, 88/91 (97%) patients showed vitamin D deficiency (<20 ng/ml), with very low vitamin D levels (<10 ng/ml) in 40 (44%) subjects. Only 15/49 (30.6%) patients of group B reached normal levels of 25-OH-vitD (≥30 ng/ml), whereas vitamin D deficiency persisted in 12/49 (24.5%) individuals. Parathormone levels inversely correlated with 25-OH-vitD (r = -0.3, p < 0.0001). Of interest, hypovitaminosis D was statistically associated with autoimmune thyroiditis (p = 0.008), while calcinosis was more frequently observed in patients of group A (p = 0.057). Moreover, we found significantly higher percentage of serum anticentromere antibodies in group B patients with 25-OH-vitD level ≥30 ng/ml (8/15 vs. 6/34; p = 0.017). In literature, hypovitaminosis D is very frequent in SSc patients. An association with disease duration, calcinosis, or severity of pulmonary involvement was occasionally recognized. Hypovitaminosis D is very frequent in SSc and severe in a relevant percentage of patients; furthermore, less than one third of supplemented subjects reached normal levels of 25-OH-vitD. The evaluation of 25-OH-vitD levels should be included in the routine clinical work-up of SSc. The above findings expand previous observations and may stimulate further investigations.


Subject(s)
Scleroderma, Systemic/blood , Vitamin D Deficiency/blood , Vitamin D/analogs & derivatives , Adult , Aged , Female , Humans , Male , Middle Aged , Parathyroid Hormone/blood , Scleroderma, Systemic/complications , Vitamin D/blood , Vitamin D Deficiency/complications , Vitamin D Deficiency/diagnosis
4.
J Biol Regul Homeost Agents ; 28(3): 481-8, 2014.
Article in English | MEDLINE | ID: mdl-25316135

ABSTRACT

The study investigated the characteristic of interstitial lung disease in a large series of systemic sclerosis (SSc) patients by means of HRCT and the correlations between functional lung parameters, serological features and the extent of lung involvement evaluated by high-resolution computed tomography (HRCT). One hundred and seven SSc patients, consecutively investigated by means of HRCT, standard chest X-ray, and pulmonary function tests, were retrospectively evaluated. Chest radiogram and HRCT scores were strongly associated (Pearson’'s r=0.82, p < .0001); moreover, the first significantly correlated with spirometric parameters, even if weakly. Anti-Scl70 and anti-centromere antibodies were associated with higher (p=0.01) and lower HRCT score (p=0.0002), respectively. The extension of interstitial lung involvement in SSc evaluated with HRCT is directly proportional to functional lung parameters. HRCT, spirometry and DLco should be considered essential in the core-set of non-invasive diagnostic tools for the first-line assessment of scleroderma lung involvement.


Subject(s)
Antibodies, Antinuclear/blood , Lung Diseases , Scleroderma, Systemic , Tomography, X-Ray Computed , Adult , Female , Follow-Up Studies , Humans , Lung/diagnostic imaging , Lung Diseases/blood , Lung Diseases/diagnostic imaging , Male , Middle Aged , Retrospective Studies , Scleroderma, Systemic/blood , Scleroderma, Systemic/diagnostic imaging
5.
Clin Rheumatol ; 32(6): 905-7, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23512377

ABSTRACT

Relapsing polychondritis is a rare immune-mediated condition, characterized by episodic inflammation of the cartilaginous tissue, in particular the ears, nose, and eyes, and involvement of joints and respiratory tract. Nearly one third of patients showed other associated diseases, such as systemic vasculitides, connective tissue diseases, or myelodysplastic syndromes. Antiphospholipid antibodies can be found in relapsing polychondritis in patients with no clinical thrombotic disease. However, when antiphospholipid syndrome is present, its clinical manifestations can be severe and life threatening. We describe the case of a patient with relapsing polychondritis associated to Budd-Chiari syndrome due to antiphospholipid syndrome. The present clinical observations together with the updated review of the literature suggest a search for antiphospholipid antibodies in all patients with relapsing polychondritis.


Subject(s)
Antiphospholipid Syndrome/complications , Budd-Chiari Syndrome/complications , Polychondritis, Relapsing/complications , Antibodies, Antiphospholipid/chemistry , Azathioprine/administration & dosage , Comorbidity , Humans , Immune System , Immunologic Factors/chemistry , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Prednisone/administration & dosage , Treatment Outcome , Warfarin/administration & dosage
6.
Reumatismo ; 64(3): 128-33, 2012 Jul 19.
Article in English | MEDLINE | ID: mdl-22842295

ABSTRACT

Anemia of chronic disorders is a typical condition of infective, immunological and neoplastic diseases. Hepcidin and proinflammatory cytokines play a leading role in its pathogenesis. Hepcidin is a hormone produced by the liver that controls iron metabolism. It ensures that iron is retained by enterocytes (where the metal is absorbed) and by macrophages (that store the iron that results from the physiological breakdown of erythrocytes). Cytokines play a role in hepcidin synthesis, and in the proliferation and the maturation of the erythroid components within bone marrow. This paper discusses the pathogenetic mechanisms of anemia in chronic disorders.


Subject(s)
Antimicrobial Cationic Peptides , Hepcidins , Anemia , Chronic Disease , Cytokines , Humans , Iron
7.
Clin Rheumatol ; 31(1): 183-7, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21989991

ABSTRACT

Eosinophilic fasciitis (EF) is a rare disease characterized by symmetrical thickness and hardening of the skin, especially localized to forearms and thorax, with eosinophilia. Corticosteroids represent the first-line therapy, even if some patients are scarcely responsive and/or may develop important side effects due to long-term treatment. Here, we describe three cases of EF, two of them refractory to previous steroid therapy, successfully treated with D-penicillamine. The present clinical observations together with the updated review of the literature suggest usefulness of D-penicillamine in EF patients, as well as its potential steroid-sparing value.


Subject(s)
Antirheumatic Agents/therapeutic use , Eosinophilia/drug therapy , Fasciitis/drug therapy , Penicillamine/therapeutic use , Drug Resistance/drug effects , Drug Substitution , Eosinophilia/diagnosis , Fasciitis/diagnosis , Female , Glucocorticoids/pharmacology , Humans , Male , Middle Aged , Treatment Outcome
8.
Reumatismo ; 59(3): 209-14, 2007.
Article in Italian | MEDLINE | ID: mdl-17898880

ABSTRACT

In the recent years, percutaneous vertebroplasty is available for the treatment of the vertebral fractures, primarily to relieve pain related to the lesion. In order to evaluate the efficacy and the safety of this technique, we have treated with percutaneous vertebroplasty, using polymethylmethacrylate, 22 patients, affected by one or more vertebral fractures caused by osteoporosis. All the patients satisfied the inclusion criteria of the American College of Radiology for percutaneous vertebroplasty. These patients were compared with a control group of 23 not treated subjects with vertebral fractures, using questionnaires for assessment of pain and quality of life, drug intake, use of corset, and tolerability of the surgery. In the large majority of patients, the treatment of osteoporotic vertebral fractures with percutaneous vertebroplasty resulted in a prompt, marked and sustained relief of vertebral pain with a persistent improvement of quality of life.


Subject(s)
Bone Cements/therapeutic use , Lumbar Vertebrae/injuries , Osteoporosis/complications , Polymethacrylic Acids/therapeutic use , Spinal Fractures/therapy , Thoracic Vertebrae/injuries , Aged , Analgesics/therapeutic use , Back Pain/drug therapy , Back Pain/etiology , Calcitriol/therapeutic use , Calcium/therapeutic use , Casts, Surgical , Combined Modality Therapy , Diphosphonates/therapeutic use , Female , Fractures, Spontaneous/diagnostic imaging , Fractures, Spontaneous/etiology , Fractures, Spontaneous/therapy , Humans , Injections, Intralesional , Male , Middle Aged , Osteoporosis/drug therapy , Patient Acceptance of Health Care , Polymethacrylic Acids/administration & dosage , Radiography, Interventional , Retrospective Studies , Spinal Fractures/diagnostic imaging , Spinal Fractures/etiology
9.
Reumatismo ; 58(3): 230-2, 2006.
Article in Italian | MEDLINE | ID: mdl-17013441

ABSTRACT

The treatment of bladder cancer with Bacillus of Calmette-Guerin (BCG) immunotherapy can induce the appearance of a reactive disorder. The Authors describe a 55-year-old male patient with bladder cancer treated with endovesical instillation of BCG immunotherapy, followed after the fifth application by asymmetric oligoarthritis and dactilitis. The observed positivity of both HLA-B27 and HLA-B51 antigens reinforces the hypothesis of a reactive form, possibly through "molecular mimicry" mechanism. The discontinuation of BCG instillation along which a therapeutic attempt with NSAD failed to improve the rheumatic manifestation, which completely remitted after a four-month course of oral steroids. No relapses of joint and tendon involvement was observed during the following five-month period. The clinico-pathogenetic implications suggested by this case are discussed.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Arthritis, Reactive/drug therapy , Arthritis, Reactive/etiology , BCG Vaccine/adverse effects , Carcinoma, Transitional Cell/therapy , Immunotherapy, Active/adverse effects , Methylprednisolone/therapeutic use , Urinary Bladder Neoplasms/therapy , Administration, Intravesical , Anti-Inflammatory Agents/administration & dosage , BCG Vaccine/administration & dosage , Carcinoma, Transitional Cell/surgery , Combined Modality Therapy , Follow-Up Studies , Humans , Male , Methylprednisolone/administration & dosage , Middle Aged , Remission Induction , Time Factors , Treatment Outcome , Urinary Bladder Neoplasms/surgery
10.
Reumatismo ; 56(2): 114-7, 2004.
Article in Italian | MEDLINE | ID: mdl-15309220

ABSTRACT

Among the different conditions causing inflammation and calcification/ossification of the soft tissues of the spinal cord, single or recurrent traumatic events are included. Within the international literature, the involvement of the posterior longitudinal ligament, following spinal cord injuries is frequently reported, especially in the elders. The Authors describe here an uncommon calcification/ossification of the anterior longitudinal ligament occurred after a double traumatic event in a young man, followed clinically and radiologically for a long-term period. On the basis of clinical, laboratory and radiological findings, the differential diagnosis with other possible aetiologies, especially DISH (Diffuse idiopathic skeletal hyperostosis) and ankylosing spondylitis, is discussed.


Subject(s)
Calcinosis , Cervical Vertebrae , Ligaments , Spondylarthropathies , Adult , Calcinosis/diagnostic imaging , Calcinosis/etiology , Cervical Vertebrae/diagnostic imaging , Cervical Vertebrae/injuries , Humans , Ligaments/diagnostic imaging , Male , Spondylarthropathies/diagnostic imaging , Spondylarthropathies/etiology , Time Factors , Tomography, X-Ray Computed
11.
Neuroscience ; 82(2): 575-89, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9466462

ABSTRACT

Chronic polyarthritis due to complete Freund's adjuvant injection is characterized by severe inflammation and pain. In the present immunocytochemical and in situ hybridization study on the rat, we quantitatively investigated peptide and peptide messenger RNA expression in the sensory circuit at the spinal level, i.e. sensory neurons in the dorsal root ganglia and in nerve endings and local neurons in the dorsal horn of the spinal cord. The immunocytochemical experiments were carried out five, 13 and 21 days after complete Freund's adjuvant injection, whereas in situ hybridization study was performed after 21 days from complete Freund's adjuvant injection. The main results in the present study are the following: (i) a decrease in substance P-, calcitonin gene-related peptide- and galanin-like immunoreactivities in dorsal root ganglia is observed five days after complete Freund's adjuvant injection, with recovery (calcitonin gene-related peptide and galanin) or even an increase (substance P) after 21 days; (ii) calcitonin gene-related peptide, substance P and galanin peptide levels are increased in dorsal root ganglia after 21 days; (iii) opioid peptide (enkephalin and dynorphin), substance P and galanin messenger RNAs are strongly up-regulated in dorsal horn neurons after 21 days; (iv) neuropeptide Y content increases in dorsal root fibres and neuropeptide Y messenger RNA levels decrease in spinal neurons after 21 days; and (v) a dramatic decrease in calcitonin gene-related peptide and cholecystokinin messenger RNA levels is found in motoneurons in the ventral horn after 21 days. These data indicate that peptide expression in dorsal root ganglia and the spinal cord is markedly influenced by severe inflammation with distinct and individual temporal patterns, which are also related to the severe rearrangement of joint structure during polyarthritis. The increase in galanin levels in dorsal root ganglia 21 days after complete Freund's adjuvant injection can be related to the structural damage of nerve fibres. Thus, there may be a transition from inflammatory to neuropathic pain, which could have consequences for treatment of patients with rheumatoid arthritis.


Subject(s)
Arthritis, Experimental/pathology , Neuronal Plasticity/physiology , Neurons, Afferent/physiology , Neuropeptides/physiology , Spinal Cord/physiology , Animals , Fluorescent Antibody Technique, Direct , Ganglia, Spinal/cytology , Ganglia, Spinal/drug effects , Ganglia, Spinal/metabolism , Immunohistochemistry , In Situ Hybridization , Male , RNA, Messenger/biosynthesis , Rats , Rats, Sprague-Dawley , Spinal Cord/cytology
13.
Clin Exp Rheumatol ; 7(4): 373-83, 1989.
Article in English | MEDLINE | ID: mdl-2591110

ABSTRACT

Skin biopsies from 4 systemic sclerosis (SSc) patients, 6 SSc patients treated with D-penicillamine (from 8 to 60 months) and 4 normal subjects were analyzed by light and electron microscopy. By light microscopy, collagen bundles of SSc dermis were thicker and more compact than in age-matched controls; D-penicillamine treatment did not significantly modify their organization. On the contrary, a stereological analysis showed that the elastin volume density was higher in patients than in controls, and increased again after D-penicillamine treatment: moreover, the number of elastin fibers per unit area was significantly higher in the dermis of patients compared to controls, and became even higher after D-penicillamine treatment. The phenomena were evident in all strata of the dermis; however, the most significant increase of elastin in SSc patients compared to controls was in the superficial dermis, whereas after D-penicillamine treatment, all the strata of the dermis showed a significant increase in the percentage of elastin and in the number of elastin fibers per unit area compared to untreated patients and to controls. There were no relationships between elastin increase and time from the onset of SSc or time and dose of D-penicillamine treatment. At the ultrastructural level, collagen fibrils had rather heterogeneous diameters and formed more compact fibers, especially in the reticular and in the deep dermis of SSc patients compared to controls. After D-penicillamine, collagen fibril diameters in three of 5 patients examined were statistically wider and more heterogeneous than in controls and in untreated patients, whereas in the other 2 subjects both the mean diameter and the distribution of the class diameter were similar to both controls and untreated patients. This could suggest a specific individual reaction to the drug. Elastin fibers were smaller, more numerous and polymorphous in all patients compared to controls. After D-penicillamine, elastin fibers became even more numerous and smaller than in untreated patients. There was no correlation between the number and size of the elastin fibers and the time or dose of D-penicillamine. The internal organization of the elastin fibers was normal. These data indicate that the amount and distribution of collagen and elastin are altered in the dermis of SSc patients, and that D-penicillamine interferes with the deposition of both fibrous proteins in the dermal extracellular space.


Subject(s)
Collagen/analysis , Elastin/analysis , Penicillamine/therapeutic use , Scleroderma, Systemic/drug therapy , Skin/analysis , Adult , Aged , Collagen/ultrastructure , Elastin/ultrastructure , Female , Fibroblasts/ultrastructure , Humans , Male , Microscopy, Electron , Middle Aged , Scleroderma, Systemic/metabolism , Scleroderma, Systemic/pathology , Skin/ultrastructure
SELECTION OF CITATIONS
SEARCH DETAIL
...